Loading
Every dated change on the records linked to Localised prostate cancer, high and very high risk, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Transdermal oestradiol suppressed testosterone as well as a luteinising hormone-releasing hormone agonist with no difference in time to first cardiovascular event (hazard ratio 1.
Per-patient sensitivity 0.
Event-free survival hazard ratio 0.
Five-year event-free survival 92 percent with adjuvant against 90 percent with salvage radiotherapy (hazard ratio 0.
Sustained castration through 48 weeks in 96.
Accuracy 92% vs 65%.
Five-year biochemical progression-free survival 85 percent with adjuvant against 88 percent with early salvage radiotherapy (hazard ratio 1.
Five-year freedom from biochemical progression 87 percent with early salvage against 86 percent with adjuvant radiotherapy (hazard ratio 1.
A milestone in how this cancer is treated.
Rate ratio for prostate cancer death 0.
5-year failure-free survival 84% in both arms, non-inferior.
Four-year overall survival 93 against 89 percent with adjuvant docetaxel added to androgen suppression and radiotherapy (hazard ratio 0.
Five-year overall survival 95 against 86 percent (hazard ratio 2.
Adding radiotherapy to lifelong androgen deprivation in locally advanced prostate cancer improved overall survival (hazard ratio 0.
Five-year overall mortality 19.
Ten-year prostate cancer mortality 11.
Metastasis-free survival hazard ratio 0.
A milestone in how this cancer is treated.